Q0249
HCPCSTocilizumab for covid-19
Official HCPCS Level II long descriptor
Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg
HCPCS Level II code Q0249 is maintained by CMS and is active in the current quarterly release.
Short descriptor
Tocilizumab for covid-19
Added to HCPCS: 2021-06-24
Nearby codes in Q0
- Q0177Hydroxyzine pamoate 25mg
- Q0180Dolasetron mesylate oral
- Q0181Unspecified oral anti-emetic
- Q0224Inj, pemivibart, 4500 mg
- Q0234Inj, tocilizumab-bavi, 1mg
- Q0235Inj, monoclon antibody, 1 mg
- Q0237Inj, tocilizumab-anoh, hospi
- Q0238Inj, tocilizumab-aazg, hospi
- Q0477Pwr module pt cable lvad rpl
- Q0478Power adapter, combo vad
- Q0479Power module combo vad, rep
- Q0480Driver pneumatic vad, rep
- Q0481Microprcsr cu elec vad, rep
- Q0482Microprcsr cu combo vad, rep
- Q0483Monitor elec vad, rep
- Q0484Monitor elec or comb vad rep
Where this code sits
Krasyn Codes for Chrome
Review coding suggestions beside a validated web workflow. Private pilot.
Request pilot accessSource
HCPCS Level II July 2026 quarterly update. Centers for Medicare & Medicaid Services (CMS), “July 2026 Alpha-Numeric HCPCS File” (HCPC2026_JUL_ANWEB_06172026.txt). Download the original file from cms.gov. Public domain (US Government work). Descriptors, billable flags and instructional notes on this page are reproduced from that file without modification. Krasyn adds no clinical guidance.